Pacira to Report First Quarter 2024 Financial Results on Tuesday May 7, 2024
Pacira to Report First Quarter 2024 Financial Results on Tuesday May 7, 2024
TAMPA, Fla., April 30, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its first quarter financial results after the close of the U.S. markets on Tuesday May 7, 2024. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET.
佛羅里達州坦帕，2024年4月30日（GLOBE NEWSWIRE）——帕西拉生物科學公司（納斯達克股票代碼：PCRX）今天宣佈，它將在2024年5月7日星期二美國市場收盤後公佈其第一季度財務業績。發佈後，該公司將在美國東部時間下午 4:30 舉辦電話會議和網絡直播。
To participate in the conference call, dial 1-800-715-9871 and provide the passcode 6363041. International callers may dial 1-646-307-1963 and use the same passcode. In addition, a live audio of the conference call will be available as a webcast. Interested parties can access the event through the "Events" page on the Pacira website at investor.pacira.com.
要參加電話會議，請撥打 1-800-715-9871 並提供密碼 6363041。國際來電者可以撥打 1-646-307-1963 並使用相同的密碼。此外，電話會議的現場音頻將以網絡直播的形式提供。感興趣的人士可以通過Pacira網站上的 “活動” 頁面訪問該活動，網址爲 investor.pacira.com。
About Pacira
關於 Pacira
Pacira BioSciences, Inc. (Nasdaq: PCRX) is committed to providing a non-opioid option to as many patients as possible to redefine the role of opioids as rescue therapy only. The company is also developing innovative interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain, and spasticity. Pacira has three commercial-stage non-opioid treatments: EXPAREL (bupivacaine liposome injectable suspension), a long-acting, local analgesia currently approved for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular, injection indicated for the management of osteoarthritis knee pain; and ioverao, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit www.pacira.com.
Pacira BioSciences, Inc.（納斯達克股票代碼：PCRX）致力於爲儘可能多的患者提供非阿片類藥物選擇，以重新定義阿片類藥物僅作爲救援療法的作用。該公司還在開發創新的干預措施，以解決涉及交感神經系統的衰弱性疾病，例如心臟電暴、慢性疼痛和痙攣。帕西拉有三種商業階段的非阿片類藥物治療方法：EXPAREL （布比卡因脂質體可注射混懸液），一種長效局部鎮痛藥，目前獲准用於術後疼痛管理；ZILRETTA （曲安奈德丙酮緩釋注射混懸液），一種緩釋的關節內注射劑，適用於治療骨關節炎膝蓋疼痛；以及 ioverao，一種新型的手持式設備，使用精確、可控的低溫劑量對目標神經進行即時、長效、無藥物的疼痛控制。要了解有關Pacira的更多信息，包括減少對阿片類藥物的過度依賴的企業使命，請訪問www.pacira.com。
Investor Contact: Pacira BioSciences, Inc. Christian Pedetti, (973) 254-4387 Christian.Pedetti@pacira.com
投資者聯繫人：Pacira BioSciences, Inc. Christian Pedetti，(973) 254-4387 Christian.Pedetti@pacira.com